Park Avenue Securities LLC Purchases 5,820 Shares of Novartis AG $NVS

Park Avenue Securities LLC raised its position in Novartis AG (NYSE:NVS) by 13.3% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 49,735 shares of the company’s stock after acquiring an additional 5,820 shares during the quarter. Park Avenue Securities LLC’s holdings in Novartis were worth $7,091,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. WCM Investment Management LLC purchased a new stake in shares of Novartis in the first quarter valued at about $220,004,000. Bank of America Corp DE increased its stake in shares of Novartis by 9.1% during the first quarter. Bank of America Corp DE now owns 4,962,794 shares of the company’s stock worth $758,067,000 after acquiring an additional 413,778 shares during the period. Miller Howard Investments Inc. NY purchased a new position in Novartis during the third quarter worth about $32,737,000. Ferguson Wellman Capital Management Inc. purchased a new position in Novartis during the first quarter worth about $27,855,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in Novartis by 40.4% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 195,986 shares of the company’s stock valued at $30,715,000 after purchasing an additional 56,424 shares during the period. 13.12% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have weighed in on NVS. Deutsche Bank Aktiengesellschaft reaffirmed a “neutral” rating on shares of Novartis in a report on Thursday, September 17th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Novartis in a report on Sunday, August 9th. Sanford C. Bernstein restated a “neutral” rating on shares of Novartis in a research note on Wednesday, July 22nd. Berenberg Bank dropped their price objective on Novartis from $147.00 to $130.00 and set a “hold” rating on the stock in a report on Friday, September 11th. Finally, HSBC upgraded Novartis from a “reduce” rating to a “hold” rating and increased their price objective for the stock from $123.00 to $136.00 in a research report on Thursday, September 10th. Six equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $152.25.

Key Novartis News

Here are the key news stories impacting Novartis this week:

• Positive Sentiment: Raised 2026 core-profit outlook: Novartis increased its forecast for full-year core operating income, citing sales growth and productivity improvements. Management also maintained its outlook for full-year sales growth. Novartis Q3 Profit Sinks 70% Despite Sales Growth; Lifts FY26 Core Income View, Backs Sales Outlook
• Positive Sentiment: Quarterly earnings beat estimates: Novartis reported adjusted earnings of $2.46 per share, above the $2.25 consensus, while revenue increased year over year. Growth from Kisqali, Kesimpta and Scemblix helped offset generic-drug pressure. NVS Q3 Earnings Top Estimates on Strong Key Drug Sales, Revenues Miss
• Neutral Sentiment: Analyst estimates remain broadly constructive: Erste Group Bank made only small changes to its forecasts, trimming its 2026 EPS estimate to $9.16 from $9.24 while raising its 2027 estimate to $9.81 from $9.80. Both remain above the broader current-year consensus of $8.91.
• Negative Sentiment: Reported profit fell sharply: Third-quarter net profit declined about 70%, largely because of a roughly $1.9 billion impairment charge and higher expenses. Although the charge is nonrecurring, it weakened headline results and may be contributing to investor caution. Novartis Raises Guidance Despite Trial Setbacks Hitting Profit
• Negative Sentiment: Execution concerns remain: Kisqali, one of Novartis’ key growth medicines, reportedly fell short of expectations, while generic competition continues to erode sales. Recent clinical-trial setbacks also add uncertainty around the company’s pipeline and future growth.

Novartis Trading Down 0.6%

Shares of NVS opened at $155.91 on Thursday. The company has a debt-to-equity ratio of 0.89, a current ratio of 0.86 and a quick ratio of 0.67. Novartis AG has a 1-year low of $121.57 and a 1-year high of $170.46. The stock has a market cap of $297.49 billion, a price-to-earnings ratio of 23.52, a price-to-earnings-growth ratio of 2.74 and a beta of 0.41. The firm has a 50 day simple moving average of $148.31 and a 200-day simple moving average of $151.61.

Novartis (NYSE:NVS) last posted its earnings results on Tuesday, October 27th. The company reported $2.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.25 by $0.21. Novartis had a return on equity of 38.56% and a net margin of 23.29%. The firm had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.53 billion. During the same quarter in the prior year, the company earned $2.25 EPS. Novartis’s revenue was up 4.4% on a year-over-year basis. Equities analysts forecast that Novartis AG will post 8.91 EPS for the current fiscal year.

Novartis Profile

Novartis AG is a Switzerland-based pharmaceutical company focused on the discovery, development and commercialization of innovative medicines. The company’s research and commercial activities span areas including cardiovascular, renal and metabolic diseases, immunology, neuroscience, oncology and hematology. Its portfolio includes prescription medicines such as Entresto, Cosentyx, Kisqali, Kesimpta, Leqvio, Pluvicto and Scemblix.

Novartis serves patients and healthcare providers in markets around the world.